Aortic stenosis (AS) is the most common form of valvular heart disease. AS of degenerative etiology is predominant. It is a persistent disease associated with the activation of 3 processes: lipid accumulation, inflammation, and calcification. Recent studies suggest that valve calcification is an actively regulated process that involves extracellular matrix remodeling, angiogenesis, and inflammation leading to bone formation. Many mechanisms and risk factors involved in the pathogenesis of AS are similar to those observed in atherosclerosis. The knowledge of these processes may play a significant role in adequate prevention and therapy of patients with AS, especially at an early stage.
Introduction Left ventricular outflow tract obstruction in adults is most often caused by aortic stenosis (AS). However, obstruction may also occur above the valve (supravalvular stenosis) or below the valve (subvalvular stenosis). AS is the most common heart valve disease in adults. It is the third cause of cardiovascular diseases after arterial hypertension and coronary artery disease. According to the Euro Heart Survey on Valvular Heart Disease, AS is the most common among single native left-sided valve diseases (43.1%). It presents primarily as degenerative AS in adults of advanced age: 2% to 7% of the patients are older than 65 years. Degenerative changes of aortic valve are observed in 20% to 30% of the patients aged more than 65 years and in about 50% of those aged more than 85 years. In 15% of the patients aged less than 65 years, AS develops within 7 years.
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Etiology and pathogenesis There are 3 primary causes of AS: 1 calcific disease of a trileaflet valve 2 congenital abnormal valve with calcification (unicuspid or bicuspid) 3 rheumatic valve disease.
Rare causes of AS include meta bolic syndromes (Fabry disease), nonspecific infectious diseases, lupus erythematosus, Paget disease, hyperuricemia, changes due to medication, and after--radiation therapy. Calcific AS develops in patients with end-stage renal disease.
According to the Euro Heart Survey on Valvular Heart Disease, degenerative etiology in AS is predominant (81.9%), followed by rheumatic origin (11.2%); endocarditis accounts for 0.8% of the cases; congenital AS with bicuspid aortic valve occurs in 5.4% of the patients; while other causes are observed in 0.6% of the patients. 1
Calcific disease Normal aortic valve is a structure consisting of several layers: valvular endothelial cells at blood-contacting surface, valvular interstitial cells, and valvular extracellular matrix including collagen, elastin, and amorphous extracellular matrix with glycosaminoglycans. Valvular inter stitial cells play a crucial role in valve function. They synthesize extracellular matrix and regulate matrix enzymes, which mediate remodeling of collagen and other matrix components.
Degenerative aortic valve disease is characterized by aortic valve leaflet thickening and calcification with normal function at the beginning. It is called aortic valve sclerosis. Progression of degenerative process is characterized by formation of calcium nodules, including the formation of actual bone and new blood vessels. In end-stage disease, large nodular calcific masses are observed in aortic leaflets. Risk factors and mediators leading to calcific AS are similar for atherosclerosis (older age, but not ACE inhibitors, slow down calcific process at an early stage of AS. 27 Oxidative stress has been demonstrated in abnormal endothelial nitric oxide synthase function, which decreases normal physio logical levels of nitric oxide along the valve endothelium. 28, 29 In calcific AS, the levels of superoxide and hydrogen peroxide are markedly increased.
The presence or progression of calcific AS has been associated with several clinical, genetic, and anatomic factors. Genetic factors play a role in selected patients. Mutations of NOTCH1 are associated with abnormal aortic valve (bicuspid aortic valve with or without aortic aneurysm) and severe aortic calcification.
30 Apolipoprotein E gene polymorphism, inter leukin-10, vitamin D receptor, and ACE are factors predisposing to the development of aortic calcification. 31, 32 Increasing age is one of the strongest predictors of cardiovascular calcification. Several regulatory mechanisms decay to exhaustion. Normal endothelial cells are damaged by blood flow; however, the endothelial surface is preserved and encrusted with dividing endothelial cells and circulating progenitor cells. The number of progenitor cells and the ability of endothelial cells to divide decrease during aging. The lack of appropriate repair processes leads to calcific AS. 33,34 The degenerative process spreads from the basal attachment of the leaflets to their edges.
Congenital abnormal valve
The most frequent cause of congenital AS is bicuspid valve accounting for about 1% to 2% of the cases worldwide. Most frequently, it arises from right coronary and noncoronary leaflet fusion. Patients with bicuspid aortic valve are more often exposed to degenerative changes and more often develop AS and aortic regurgitation. These valve diseases are observed in the 4th or 5th decade of life. They usually occur in isolation but are associated with other abnormalities in 20% of the cases, the most common being coarctation of the aorta or patent ductus arteriosus.
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Rheumatic valve disease Rheumatic valve disease results from adhesion and fusion of the commissures between the leaflets with small central orifice. Nowadays, rheumatic fever is very rare. Contrary to degenerative aortic valve, rheumatic changes spread from the edges of leaflets and their commissures. Rheumatic disease nearly always affects the mitral valve first, so that rheumatic aortic valve disease is accompanied by rheumatic mitral valve changes. 
3,4 Mechanical stress (e.g., elevated stretch, shear stresses) on aortic valve leads to valvular endothelial dysfunction, followed by deposition of low-density lipoprotein, lipoprotein A, with evidence of lipoprotein oxidation, as well as inflammatory cells with T-lymphocytes and macrophages, which in turn activate valvular inter stitial cells resulting in their osteoblastic transformation. 5-11 Cytokines, such as interleukin-1 and tumor necrosis factor-α, are markedly elevated in stenotic valves.
5,6 Recent studies suggest that valve calcification is an actively regulated process, which involves local production of proteins that promote tissue calcification. Several extracellular matrix proteins typically found in bones, for example osteocalcin, osteopontin, osteonectin, bone morphogenetic protein, and meta lloproteinases, are present in cardiovascular calcification, including cardiac valves. [12] [13] [14] [15] [16] Osteopontin expression has been demonstrated in the mineralization zones of calcified aortic valves obtained during necropsy or surgery. 7 There is a complex inter action between the receptor activator of nuclear factor κB (RANK) and its ligand (RANKL) and osteoprotegerin in relation to oxidative stress and inflammation. 17, 18 This inter action plays an important role in calcification.
Patho logical angiogenesis has been observed in calcific AS. Inflammatory mediators cause an increase in vascular endothelial growth factor-A (VEGF-A) and transforming growth factor-β (TGF-β).
19-21 VEGF-A and TGF-β induce fibrosis and contribute to the progression of calcific AS. TGF-β1 may contribute to the progression of calcific AS by initiating apoptosis-associated mineralization of aortic valve inter stitial cells. 22 A number of authors have reported that the activation of angiogenesis in aortic valves occurs in a close association with valvular stenosis. Angiogenesis is involved in remodeling of the aortic valve and formation of calcified valves. 23 In later stages, the aortic valve shows extensive thickening and matrix remodeling due to increasing cell proliferation, matrix synthesis, and activation of matrix meta lloproteinases. They degrade all components of the extracellular matrix including fibrillar collagen. 24 A recent study suggested that meta lloproteinases lead not only to matrix degradation, but may also directly promote the proliferation of fibroblasts to cause tissue thickening. 25 The authors underline the role of the renin--angiotensis system. Angiotensin II leads to oxidative stress and inflammation and contributes to accelerated degeneration of valve leaflets.
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Angiotensin-converting enzyme (ACE) and angiotensin I have been found to be increased in stenotic valves. A retrospective clinical study suggested that angiotensin type I receptor blockers, The increased risk of bleeding appears to be due to patho logical function of platelets and decreased concentration of the von Willebrand factor. This abnormality results from mechanical disruption of von Willebrand multimers during turbulent passage through the narrowed valve. The severity of the von Willebrand factor abnormality is directly related to the severity of AS and transvalvular gradient.
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Conclusions The knowledge of the pathogenesis and mechanisms of developing AS is particularly important. Reduction in risk factors of, for the stenotic valve results from increased resistance (related to the narrowing of the valve opening) and turbulence distal to the valve. The magnitude of the pressure gradient is determined by the severity of stenosis and the flow rate across the valve. Obstruction of the left ventricular outflow results in pressure overload, with compensatory hypertrophy of the left ventricle to maintain normal wall stress, preserving systolic function. Narrowing of the aortic orifice to half its size causes little obstruction to the left ventricular outflow and only a small pressure gradient exists across the valve. Reduced valve area results in progressively greater left ventricular pressure overload and the development of left ventricular hypertrophy as a major compensatory mechanism. As hypertrophy continues to develop, the left ventricle becomes less compliant and left ventricular end-diastolic pressure can become elevated even though the ventricular size remains normal. Left ventricular diastolic function is reduced. Excessive hypertrophy may cause decreased coronary blood flow reserve. Long-lasting hypertrophy leads to increased collagen synthesis, inter stitial fibrosis, and myocyte degeneration. In some patients, hypertrophy fails to normalize afterload allowing the abnormal afterload to reduce ventricular ejection performance, reducing cardiac output, adding to the heart failure syndrome. 36
Classification The normal aortic valve orifice is 3.0 to 4.0 cm 2 . AS becomes hemo dynamically significant when the area is about 1 cm 2 . The European Society of Cardiology categorizes AS severity as mild, moderate, or severe to provide guidance for clinical decision-making. The simplest measure of the extent of stenosis is the forward velocity across the aortic valve. This velocity is about 1.0 m/s in normal state and increases to 2.6 to 2.9 m/s in mild stenosis, 3.0 to 4.0 m/s in moderate stenosis, and more than 4.0 m/s severe stenosis (fIguREs 1, 2, 3) .
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Natural history AS is a chronic progressive disease. For a long time, patients remain asymptomatic despite the obstruction and increased pressure load on the left ventricle. However, the duration of asymptomatic phase varies widely among individuals. A recent study showed that the probability of living 5 years without cardiovascular events is below 50% in asymptomatic patients. Predictors of rapid progression of valve disease include age under 50 years, coronary artery disease, elevated brain natriuretic peptide, large calcific aortic valve, and increased velocity across the aortic valve under 4 m/s. Sudden cardiac death is a frequent cause of death in symptomatic patients but appears to be rare in the asymptomatic group. Clinical symptoms cause deterioration, and some authors have reported symptom-free survival at 2 years ranging from 20% to 50% of patients.
Patients with AS are at increased risk of bleeding. In some patients, it is due to angiodysplasia. 
